Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Cisplatin and IV Paclitaxel in Epithelial Ovarian Cancer After Neoadjuvant Chemotherapy and Surgery
NCT00889733Phase 2Terminated
- Sponsor
- University Health Network
- Start
- Feb 2007
- Primary completion
- Jul 2009
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in epithelial ovarian cancer (EOC), sponsored by University Health Network. Primary endpoint: Safety and Dose Tolerance. Started Feb 2007; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT00889733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00889733.